Limited efficacy of 18F-FDG PET/CT for differentiation between metastasis-free pancreatic cancer and mass-forming pancreatitis

Clinical Nuclear Medicine

Volumn 38, Issue 6, 2013, Pages 417-421

  Kato, Katsuhiko ^a   Nihashi, Takashi ^b   Ikeda, Mitsuru ^a   Abe, Shinji ^b   Iwano, Shingo ^a   Itoh, Shigeki ^c   Shimamoto, Kazuhiro ^a   Naganawa, Shinji ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

18F FDG PET CT; Mass forming pancreatitis; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AUTOIMMUNE PANCREATITIS; CANCER PATIENT; CANCER SCINTISCANNING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CT SPECT SCANNER; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS SCINTISCANNING; PANCREATITIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PANCREATITIS;

EID: 84877610684     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182817d9d     Document Type: Article

References (29)

1. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994;192:79-86.
2. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F]- fluoro-2-deoxy-D-glucose positron emission tomography. Gut. 1995;36:771-777.
3. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology. 1995;195:345-352.
4. Keogan MT, Tyler D, Clark L, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR. 1998;171:1565-1570.
5. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784-1791.
6. van Kouwen MC, Jansen JB, van Goor H, et al. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging. 2005;32:399-404.
7. Heinrich S, Goerres GW, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243.
8. Ruf J, Lopez Hänninen E, Oettle H, et al Detection of recurrent pancreatic cancer: comparison of FDG-PETwith CT/MRI. Pancreatology. 2005;5:266-272
9. Miura F, Takada T, Amano H, et al. Diagnosis of pancreatic cancer. HPB. 2006;8:337-342.
10. Kauhanen SP, Komar G, Seppänen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957-963.
11. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg. 2004;11:4-10.
12. Nakamoto Y, Higashi T, Sakahara H, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med. 2000;25:115-119.
13. Diederichs CG, Staib L, Vogel J, et al. Values and limitations of 18Ffluorodeoxyglucose- positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas. 2000;20:109-116.
14. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy- Dglucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-2554.
15. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18- fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
16. Tahara T, Ichiya Y, Kuwabara Y, et al. High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr. 1989;13: 829-831.
17. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647-1649.
18. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259-264.
19. Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144-151.
20. Neff CC, Simeone JF, Wittenberg J, et al. Inflammatory pancreatic masses. Problems in differentiating focal pancreatitis from carcinoma. Radiology. 1984;150:35-38.
21. Takase M, Suda K. Histopathological study on mechanism and background of tumor-forming pancreatitis. Pathol Int. 2001;51:349-354.
22. Kennedy T, Preczewski L, Stocker SJ, et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. Am J Surg. 2006;191:437-441.
23. Momtahen AJ, Balci NC, Alkaade S, et al. Focal pancreatitis mimicking pancreatic mass: magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP) findings including diffusion-weighted MRI. Acta Radiol. 2008;49:490-497.
24. Members of the Criteria Committee for Autoimmune Pancreatitis of the Japan Pancreas Society. Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society. J Jpn Pancreas (Suizou). 2002;17:587.
25. Smith CD, Behrns KE, van Heerden JA, et al. Radical pancreatoduodenectomy for misdiagnosed pancreatic mass. Br J Surg. 1994;81:585-589.
26. Abraham SC, Wilentz RE, Yeo CJ, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol. 2003;27:110-120.
27. van Gulik TM, Reeders JW, Bosma A, et al. Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. Gastrointest Endosc. 1997;46:417-423.
28. Hardacre JM, Iacobuzio-Donahue CA, Sohn TA, et al. Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg. 2003;237:853-858.
29. Ho CL, Dehdashti F, Griffeth LK, et al. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr. 1996;20:363-369.